Each tablet contains:
Losartan Potassium           25 mg           

Pharmacological properties:
Losartan and its principle active metabolite block the vasconstrictor and aldosterone secreting effects of angiotensin II by selectively blocking the binding of angiotensin.
II to the receptor found in many tissues. Neither losartan nor its active metabolite bind to or block hormone receptors or ion channels known to be important in cardiovascular regulation.

Losartan undergoes the first pass metabolism by cytochrome P450 enzymes. It is converted to an active carboxylic acid metabolite.
The terminal half life of losartan is about 2 hours and of the metabolite is 6-9 hours.
Mean peak concentrations of losartan and its active metabolites are reached in 1 hour and 3–4 hours respectively. Both losartan and its active metabolite are highly bound to plasma proteins, primarily albumin.

Aratins is indicated for the treatment of hypertension. It may be used alone or in combination with other anti hypertensive agents.


Losartan is contraindicated in patients who are hypersensitive to any component of this product.

-    A lower dose should be considered for patients with impaired liver function.
-    In patients whose renal function may depend on the activity of the rennin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors has been associated with oliguria and/or progressive azotemia.

Drug interaction:
Concomitant use of potassium sparing diuretics (e.g. spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.

When pregnancy is detected, Aratins should be discontinued as soon as possible.

Because of the potential adverse effects on the infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Side Effects:
The side effects that may occur include diarrhea, muscle cramp, cough, dizziness, nasal congestion as well as swelling of the larynx and glottis.

The most likely manifestation of Overdosage would be hypotension and tachycardia. Bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension occurs, supportive treatment should be instituted.

Dosage and Administration:

The usual starting dose of Aratins is 50 mg once daily, 25 mg in patients with possible depletion intravascular volume, e.g. patients treated with diuretics and patients with a history of hepatic impairment.
Aratins can be administered once or twice daily with total daily doses ranging from 25 mg to 100 mg.

Therapeutic category:
Antihypertensive, angiotensin II receptor antagonist.
                                        Legal category: POM

Box contain 10 tablet in one strip.